{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:57:22Z","timestamp":1792637842853,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Takotsubo syndrome (TTS) is an acute cardiac condition marked by transient left ventricular dysfunction. Pharmacological management is largely empirical. SGLT2 inhibitors (SGLT2i) offer cardioprotective effects in other cardiovascular diseases, but their impact in TTS is unclear. We thus aim to evaluate whether SGLT2i improves long-term survival after TTS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a trial emulation based on real-world data of the TriNetX global network, including patients with TTS diagnosed October 2019\u2013August 2025 (n = 31 018). The primary analysis emulated a de novo pharmacotherapy initiator cohort with a \u226472-h post-diagnosis enrolment window, evaluating the addition of SGLT2i to RAAS inhibitors (RAASi) and beta-blockers (BB). Follow-up began at pharmacotherapy initiation; two-year survival was analysed. Propensity-score matching was performed for age, sex, diabetes, hypertension, dyslipidemia, renal function, initial left ventricular function at diagnosis, and acute severity markers. The median follow-up was 13.3 months. Two-year mortality was 17.5%. After matching (yielding well-balanced 524 patients per group), mortality was significantly reduced in the SGLT2i group compared with RAASi + BB alone (HR 0.56, 95% CI 0.36\u20130.89). Results were consistent in an extended \u226430-day virtual-enrolment window. A supportive multivariable Cox model considered overall exposure to different therapies (n = 31 018). SGLT2i were associated with the largest reduction in mortality, followed by angiotensin receptor blockers, ACE inhibitors, and BB. Sacubitril\/valsartan and MRAs showed no significant association with mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the largest real-world TTS cohort, SGLT2i were associated with lower long-term mortality. These findings support their consideration in TTS management and justify randomized trials to evaluate SGLT2i as adjunctive therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf088","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:36:25Z","timestamp":1765802185000},"page":"75-84","source":"Crossref","is-referenced-by-count":7,"title":["SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7919-4113","authenticated-orcid":false,"given":"Elias","family":"Rawish","sequence":"first","affiliation":[{"name":"Medical Clinic II, University Heart Center L\u00fcbeck, University Hospital Schleswig-Holstein , 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research) , Partner Site Hamburg\/Kiel\/L\u00fcbeck, 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"University Heart Centre L\u00fcbeck , University Hospital Schleswig-Holstein, 23538 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Lemmer","sequence":"additional","affiliation":[{"name":"Medical Clinic II, University Heart Center L\u00fcbeck, University Hospital Schleswig-Holstein , 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"University Heart Centre L\u00fcbeck , University Hospital Schleswig-Holstein, 23538 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kurz","sequence":"additional","affiliation":[{"name":"Medical Clinic II, University Heart Center L\u00fcbeck, University Hospital Schleswig-Holstein , 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research) , Partner Site Hamburg\/Kiel\/L\u00fcbeck, 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"University Heart Centre L\u00fcbeck , University Hospital Schleswig-Holstein, 23538 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Mezger","sequence":"additional","affiliation":[{"name":"Medical Clinic II, University Heart Center L\u00fcbeck, University Hospital Schleswig-Holstein , 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research) , Partner Site Hamburg\/Kiel\/L\u00fcbeck, 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"University Heart Centre L\u00fcbeck , University Hospital Schleswig-Holstein, 23538 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"P\u00e4tz","sequence":"additional","affiliation":[{"name":"Medical Clinic II, University Heart Center L\u00fcbeck, University Hospital Schleswig-Holstein , 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"University Heart Centre L\u00fcbeck , University Hospital Schleswig-Holstein, 23538 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-3741","authenticated-orcid":false,"given":"Thomas","family":"Stiermaier","sequence":"additional","affiliation":[{"name":"Medical Clinic II, University Heart Center L\u00fcbeck, University Hospital Schleswig-Holstein , 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research) , Partner Site Hamburg\/Kiel\/L\u00fcbeck, 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"University Heart Centre L\u00fcbeck , University Hospital Schleswig-Holstein, 23538 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6442-246X","authenticated-orcid":false,"given":"Ingo","family":"Eitel","sequence":"additional","affiliation":[{"name":"Medical Clinic II, University Heart Center L\u00fcbeck, University Hospital Schleswig-Holstein , 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research) , Partner Site Hamburg\/Kiel\/L\u00fcbeck, 23538 L\u00fcbeck ,","place":["Germany"]},{"name":"University Heart Centre L\u00fcbeck , University Hospital Schleswig-Holstein, 23538 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2026022706314090400_pvaf088-B1","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehy076","article-title":"International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur Heart J"},{"key":"2026022706314090400_pvaf088-B2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/jcm10030479","article-title":"Current knowledge and future challenges in Takotsubo syndrome: part 1-pathophysiology and diagnosis","volume":"10","author":"Rawish","year":"2021","journal-title":"J Clin Med"},{"key":"2026022706314090400_pvaf088-B3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ejhf.494","article-title":"Long-term excess mortality in Takotsubo cardiomyopathy: predictors, causes and clinical consequences","volume":"18","author":"Stiermaier","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026022706314090400_pvaf088-B4","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf101","article-title":"Mental health status and quality-of-life after an acute myocardial infarction with non-obstructive coronary arteries or takotsubo syndrome: a systematic review","author":"Leissner","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026022706314090400_pvaf088-B5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/jcm10030468","article-title":"Current knowledge and future challenges in Takotsubo syndrome: part 2-treatment and prognosis","volume":"10","author":"Santoro","year":"2021","journal-title":"J Clin Med"},{"key":"2026022706314090400_pvaf088-B6","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jacc.2020.10.060","article-title":"Pathophysiology of Takotsubo syndrome: JACC state-of-the-art review","volume":"77","author":"Lyon","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026022706314090400_pvaf088-B7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jchf.2024.11.015","article-title":"Beta-blockers and long-term mortality in Takotsubo syndrome: results of the multicenter GEIST registry","volume":"13","author":"Raposeiras-Roubin","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026022706314090400_pvaf088-B8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ahj.2024.08.019","article-title":"Renin angiotensin system inhibitors and outcome in patients with takotsubo syndrome: a propensity score analysis of the GEIST registry","volume":"278","author":"Santoro","year":"2024","journal-title":"Am Heart J"},{"key":"2026022706314090400_pvaf088-B9","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/ehf2.14713","article-title":"Effects of pharmacological interventions on mortality in patients with Takotsubo syndrome: a report from the SWEDEHEART registry","volume":"11","author":"Petursson","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026022706314090400_pvaf088-B10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jjcc.2025.01.009","article-title":"Clinical characteristics and outcomes in takotsubo syndrome -review of insights from the InterTAK registry","volume":"85","author":"Kato","year":"2025","journal-title":"J Cardiol"},{"key":"2026022706314090400_pvaf088-B11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12933-023-01970-w","article-title":"Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies","volume":"22","author":"Carluccio","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026022706314090400_pvaf088-B12","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-023-39590-3","article-title":"Acute stress induces long-term metabolic, functional, and structural remodeling of the heart","volume":"14","author":"Yoganathan","year":"2023","journal-title":"Nat Commun"},{"key":"2026022706314090400_pvaf088-B13","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.118.037975","article-title":"Myocardial and systemic inflammation in acute stress-induced (Takotsubo) cardiomyopathy","volume":"139","author":"Scally","year":"2019","journal-title":"Circulation"},{"key":"2026022706314090400_pvaf088-B14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"2026022706314090400_pvaf088-B15","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026022706314090400_pvaf088-B16","doi-asserted-by":"crossref","first-page":"108861","DOI":"10.1016\/j.pharmthera.2025.108861","article-title":"Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure","volume":"270","author":"Armillotta","year":"2025","journal-title":"Pharmacol Ther"},{"key":"2026022706314090400_pvaf088-B17","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2022.03.353","article-title":"Sodium glucose cotransporter-2 inhibition for acute myocardial infarction","volume":"79","author":"Udell","year":"2022","journal-title":"JACC"},{"key":"2026022706314090400_pvaf088-B18","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"2026022706314090400_pvaf088-B19","doi-asserted-by":"crossref","first-page":"ehae666-3732","DOI":"10.1093\/eurheartj\/ehae666.3732","article-title":"Takotsubo syndrome induced oxidative stress and endothelial dysfunction in left ventricle of rat model: association with NADPH oxidases\/SGLT2 pro- oxidant pathway","volume":"45","author":"Tatarcheh","year":"2024","journal-title":"Eur Heart J"},{"key":"2026022706314090400_pvaf088-B20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jacc.2018.06.016","article-title":"Long-term prognosis of patients with Takotsubo syndrome","volume":"72","author":"Ghadri","year":"2018","journal-title":"JACC"},{"key":"2026022706314090400_pvaf088-B21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.recesp.2024.12.008","article-title":"Rationale and design of the beta-blockers in Tako-tsubo syndrome study: a randomized clinical trial (\u03b2-Tako)","volume":"78","author":"Alfonso","year":"2025","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026022706314090400_pvaf088-B22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ahj.2022.11.010","article-title":"Rationale and design of BROKEN-SWEDEHEART: a registry-based, randomized, parallel, open-label multicenter trial to test pharmacological treatments for broken heart (Takotsubo) syndrome","volume":"257","author":"Omerovic","year":"2023","journal-title":"Am Heart J"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf088\/66438808\/pvaf088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/2\/75\/66438808\/pvaf088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/2\/75\/66438808\/pvaf088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:31:49Z","timestamp":1772191909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/2\/75\/8428382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,19]]},"published-print":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf088","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]}}}